Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How long does kesimpta stay in your body?How is vascepa's fda approval process progressing?What role did lipitor's marketing play in post patent success?What evidence supports sapropterin's effect on memory?How has lipitor affected your vegetable consumption?
See the DrugPatentWatch profile for Tenofovir
When Does Tenofovir Alafenamide Patent Expiry? Tenofovir alafenamide, a medication used to treat HIV and hepatitis B, is covered by a patent held by Gilead Sciences, the manufacturer of the drug. According to DrugPatentWatch.com [1], the patent for tenofovir alafenamide (Vemlidy, Viread) expires in the United States on December 18, 2031. Why Are Companies Challenging the Tenofovir Alafenamide Patent? Several pharmaceutical companies, including Teva Pharmaceutical Industries, have challenged the patent for tenofovir alafenamide in the United States, seeking to market generic versions of the drug. These challenges are based on the argument that the patent for the drug is invalid or that the claims made in the patent are too broad [2]. How Does the Patent Expiry Impact the Market? The expiry of the patent for tenofovir alafenamide is expected to lead to the entry of generic versions of the drug into the market, which could increase competition and potentially lower prices for consumers. This, in turn, could make the drug more accessible to patients who are currently unable to afford it. What's the Regulatory Climate for Generic Tenofovir Alafenamide? The US Food and Drug Administration (FDA) has approved several generic versions of tenofovir alafenamide, which are available in the market. The FDA has also granted tentative approval to several additional generic versions of the drug [3]. Can Biosimilars Enter the Market Before Patent Expiry? Under the Biologics Price Competition and Innovation Act of 2009, biosimilars can be approved by the FDA before the patent expiry of the original product. However, the company developing the biosimilar must demonstrate that it meets the same standards of safety and efficacy as the original product. Sources: [1] DrugPatentWatch.com. (2023). Tenofovir alafenamide (Vemlidy, Viread) patent summary. [2] Teva Pharmaceutical Industries. (2020). Teva receives FDA approval for Viread (Tenofovir Disoproxil Fumarate) Tablets. [3] FDA. (2022). Tentative approvals.
Other Questions About Tenofovir :